Trial Profile
Comparison of Vision and Development Outcomes in Laser- and Bevacizumab-Treated Infants With Retinopathy of Prematurity
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 12 Sep 2023 Status changed from active, no longer recruiting to completed.
- 22 Aug 2022 Planned End Date changed from 1 Oct 2021 to 1 Oct 2023.
- 22 Aug 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2023.